2020
Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults
Viera A, Bromberg DJ, Whittaker S, Refsland BM, Stanojlović M, Nyhan K, Altice FL. Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults. Epidemiologic Reviews 2020, 42: 41-56. PMID: 32239206, PMCID: PMC8087870, DOI: 10.1093/epirev/mxaa001.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBuprenorphineChildHumansMethadoneNaltrexoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersYoung AdultConceptsOpioid use disorderUse disordersYoung adultsAssociation of ageFull-text reviewRetention of adolescentsConcurrent substance useNegative health outcomesMOUD retentionOpioid epidemicInclusion criteriaHealth outcomesYounger ageAge groupsMOUDSubstance useAdherenceGood evidenceAdultsMedicationsDisordersAdolescentsSearch criteriaAgeOutcomes
2019
HIV, Drug Injection, and Harm Reduction Trends in Eastern Europe and Central Asia: Implications for International and Domestic Policy
LaMonaca K, Dumchev K, Dvoriak S, Azbel L, Morozova O, Altice FL. HIV, Drug Injection, and Harm Reduction Trends in Eastern Europe and Central Asia: Implications for International and Domestic Policy. Current Psychiatry Reports 2019, 21: 47. PMID: 31161306, PMCID: PMC6685549, DOI: 10.1007/s11920-019-1038-8.Peer-Reviewed Original ResearchConceptsOpioid agonist therapySyringe services programDrug injectionAntiretroviral therapyHIV epidemicEvidence-based HIV prevention strategiesNew HIV casesHIV prevention strategiesHarm reduction programsAgonist therapyHIV incidenceHIV casesRecent FindingsThoughPrevention strategiesSexual partnersHIVInjectionTherapyReduction programsEpidemicPunitive drug lawsService programsMortalityCliniciansIncidenceTreating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes
Makarenko I, Pykalo I, Springer SA, Mazhnaya A, Marcus R, Filippovich S, Dvoriak S, Altice FL. Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes. Journal Of Substance Use And Addiction Treatment 2019, 104: 34-41. PMID: 31370983, PMCID: PMC8215516, DOI: 10.1016/j.jsat.2019.05.008.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist treatmentXR-NTX injectionXR-NTX treatmentXR-NTXUrine drug testingOpioid useExtended-release naltrexoneMonths of treatmentThree-month outcomeHealth-related qualityAdverse side effectsSymptoms of depressionOpioid dependenceAgonist treatmentLife scoresTreatment optionsIndependent factorsSide effectsUse disordersPeriod of observationDrug useStimulant useTreatment motivationDrug testing
2018
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 92-100. PMID: 29781884, PMCID: PMC6092223, DOI: 10.1097/qai.0000000000001759.Peer-Reviewed Original ResearchConceptsAlcohol use disorderViral suppressionExtended-release naltrexoneXR-NTXPlacebo groupPlacebo-controlled trialMonthly injectionsSecondary outcomesTreat analysisIncarcerated individualsEligible participantsWhite raceUse disordersAlcohol consumptionHIVMonthsNaltrexoneBaselineDisordersInjectionIncarcerated peopleParticipantsPlaceboGroupSuppressionExtended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
Springer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCriminal LawDelayed-Action PreparationsDouble-Blind MethodFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansInjections, IntramuscularMaleMiddle AgedMultivariate AnalysisNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPrisonersProspective StudiesResearch DesignRNA, ViralTime FactorsTreatment OutcomeViral LoadConceptsOpioid use disorderViral suppressionXR-NTXPlacebo groupPrimary outcomeUse disordersXR-NTX groupPlacebo-controlled trialExtended-release naltrexoneStatistical significant differenceRelease naltrexoneMonthly injectionsEligible participantsTreatment groupsJail detaineesHIVMonthsBaselinePlaceboSignificant differencesNaltrexoneJail inmatesDisordersVS levelsOutcomesConcurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine
Makarenko I, Mazhnaya A, Marcus R, Pykalo I, Madden L, Filippovich S, Dvoriak S, Altice FL. Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine. Journal Of Substance Use And Addiction Treatment 2018, 87: 1-8. PMID: 29471921, PMCID: PMC5826566, DOI: 10.1016/j.jsat.2018.01.007.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentMethadone maintenance treatmentConcurrent illicit drug useOAT patientsIllicit drug useDrug injectionDrug useAgonist treatmentUse disordersMultivariable logistic regressionConcurrent drug useOngoing drug usePolysubstance use disorderAlcohol use disorderMaintenance treatmentIndependent correlatesBMT programSevere opioidDrug injectingPatientsHealth outcomesTreatment dropoutAlcohol dependenceInjection initiationYounger ageA qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine
Marcus R, Bojko MJ, Mazhnaya A, Makarenko I, Filippovych S, Dvoriak S, Altice FL, Springer SA. A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine. Journal Of Substance Use And Addiction Treatment 2018, 86: 86-93. PMID: 29415856, PMCID: PMC5808584, DOI: 10.1016/j.jsat.2018.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultDelayed-Action PreparationsFemaleFocus GroupsHumansMaleNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPatient PreferenceUkraineConceptsOpioid agonist therapyXR-NTXExtended-release naltrexonePsychological supportOpioid use disorderHIV prevention effortsFocus groupsPerceptions of recoveryAgonist therapyOpioid withdrawalYoung PWIDOpioid antagonistPatient preferencesNew pharmacotherapiesPsychoactive medicationsInjection careerUse disordersFocus group transcriptsPWIDPrevention effortsNaltrexoneGroup transcriptsIndividual barriersTreatmentWithdrawal
2017
Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine
Marcus R, Makarenko I, Mazhnaya A, Zelenev A, Polonsky M, Madden L, Filippovych S, Dvoriak S, Springer SA, Altice FL. Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine. Drug And Alcohol Dependence 2017, 179: 213-219. PMID: 28806638, PMCID: PMC5599372, DOI: 10.1016/j.drugalcdep.2017.07.010.Peer-Reviewed Original ResearchMeSH KeywordsHumansInjectionsNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPatient PreferenceUkraineConceptsOpioid agonist therapyOpioid use disorderExtended-release naltrexoneXR-NTXHIV preventionIndependent correlatesPatient preferencesUse disordersShort-term injectorsPatient-centered treatmentAgonist therapyPharmacological therapyHIV incidenceTreatment optionsPWIDTreatment entryAddiction treatmentPreventionNaltrexoneShort durationTherapyNegative attitudesDisordersNew optionsTreatmentExtended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community
Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug And Alcohol Dependence 2017, 174: 158-170. PMID: 28334661, PMCID: PMC5407009, DOI: 10.1016/j.drugalcdep.2017.01.026.Peer-Reviewed Original ResearchConceptsHeavy drinking daysAlcohol use disorderFirst heavy drinking dayExtended-release naltrexoneXR-NTXDrinking daysPlacebo groupAlcohol consumptionDrinks/drinking dayPlacebo-controlled trialSerious adverse eventsDrinks/daySignificant differencesMonthly injectionsAdverse eventsHIV diseaseHIV outcomesTreatment armsAlcohol scoresMAIN OUTCOMEAlcohol consumption scoresUse disordersImprovement scoresDrinking outcomesNaltrexone
2015
Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system
Springer SA, Brown SE, Di Paola A, Altice FL. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug And Alcohol Dependence 2015, 157: 158-165. PMID: 26560326, PMCID: PMC4675147, DOI: 10.1016/j.drugalcdep.2015.10.023.Peer-Reviewed Original ResearchConceptsAlcohol use disorderExtended-release naltrexoneOpioid use disorderXR-NTXUse disordersHIV diseaseFirst injectionDouble-blind placebo-controlled randomized trialSecond injectionPlacebo-controlled randomized trialSubstance use disordersMultivariate regression analysisTreatment of alcoholCorrelates of retentionAntiretroviral therapyStudy drugHIV infectionRandomized trialsUrine testsUrine screensEligible personsDays of releaseHazardous drinkingCocaine useDemographic featuresBalancing access and safety in prescribing opioid agonist therapy to prevent HIV transmission
Bachireddy C, Weisberg DF, Altice FL. Balancing access and safety in prescribing opioid agonist therapy to prevent HIV transmission. Addiction 2015, 110: 1869-1871. PMID: 26464200, DOI: 10.1111/add.13055.Peer-Reviewed Original ResearchMen Who Have Sex With Men in Peru: Acceptability of Medication-Assisted Therapy for Treating Alcohol Use Disorders
Brown SE, Vagenas P, Konda KA, Clark JL, Lama JR, Gonzales P, Sanchez J, Duerr AC, Altice FL. Men Who Have Sex With Men in Peru: Acceptability of Medication-Assisted Therapy for Treating Alcohol Use Disorders. American Journal Of Men's Health 2015, 11: 1269-1278. PMID: 25787988, PMCID: PMC4573823, DOI: 10.1177/1557988315576775.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcoholismFocus GroupsHomosexuality, MaleHumansMaleNaltrexoneNarcotic AntagonistsPatient Acceptance of Health CarePeruConceptsMSM/transgender womenAlcohol use disorderMedication-assisted therapyTransgender womenUse disordersManagement of AUDAntiretroviral therapy adherenceAlcohol problemsRisky sexual behaviorPeruvian MSMTherapy adherenceClinical trialsHIV epidemicTreatment programTotal abstinenceLess alcoholTherapyThematic content analysisMultiple studiesMedicationsSexual behaviorHIVDrinking behaviorMenFamily support
2014
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community
Di Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL, Springer SA. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemporary Clinical Trials 2014, 39: 256-268. PMID: 25240704, PMCID: PMC4283549, DOI: 10.1016/j.cct.2014.09.002.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentPlacebo-controlled trialXR-NTXAgonist treatmentOpioid dependenceTreatment outcomesPoor HIV treatment outcomesOpioid treatment outcomesOpioid-dependent prisonersExtended-release naltrexoneHIV treatment outcomesHIV transmission riskEvidence-based treatmentsCriminal justice settingsEarly acceptabilityStudy medicationFirst injectionStudy acceptabilityHIVTotal referralsJail detaineesCommunity settingsTransmission riskDrug relapseHigh internal validitySelf-Management of Buprenorphine/Naloxone Among Online Discussion Board Users
Brown SE, Altice FL. Self-Management of Buprenorphine/Naloxone Among Online Discussion Board Users. Substance Use & Misuse 2014, 49: 1017-1024. PMID: 24779501, PMCID: PMC5592159, DOI: 10.3109/10826084.2014.888449.Peer-Reviewed Original ResearchAn evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone
Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. Journal Of Substance Use And Addiction Treatment 2014, 47: 35-40. PMID: 24674234, PMCID: PMC4042403, DOI: 10.1016/j.jsat.2014.02.008.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialXR-NTXGamma-glutamyl transferaseAlanine aminotransferaseMental illnessAspartate aminotransferaseRandomized placebo-controlled trialMonthly injectable formulationXR-NTX armExtended-release naltrexoneHepatic enzyme elevationHepatic enzyme levelsRelease naltrexoneAntiretroviral therapyHCV infectionBaseline characteristicsHepatic transaminasesEnzyme elevationPsychiatric medicationsHepatotoxicity concernsGlutamyl transferaseAlcohol dependenceOpioidsHIVNaltrexone
2013
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community
Springer SA, Altice FL, Herme M, Di Paola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemporary Clinical Trials 2013, 37: 209-218. PMID: 24384538, PMCID: PMC3992862, DOI: 10.1016/j.cct.2013.12.006.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialHIV treatment outcomesTreatment outcomesCriminal justice system (CJS) populationsPoor antiretroviral therapy (ART) adherenceAlcohol useExtended-release naltrexoneAntiretroviral therapy adherenceMedication-assisted therapyPrevention of relapseAlcohol use disorderSexual risk-taking behaviorsAlcohol-dependent personsXR-NTXHigh morbidityTherapy adherenceAlcohol relapseHigh prevalenceStudy participationEligibility criteriaUse disordersHIVRelapseHazardous drinkingNaltrexone
2011
HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study
Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R. HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s22-s32. PMID: 21317590, PMCID: PMC3263431, DOI: 10.1097/qai.0b013e318209751e.Peer-Reviewed Original ResearchConceptsBUP/NXHIV treatment outcomesCD4 lymphocyte countHIV clinical care settingsAntiretroviral therapyViral suppressionLymphocyte countTreatment outcomesClinical care settingsOpioid dependenceCare settingsLower HIV-1 RNA levelsBuprenorphine/naloxone treatmentHIV-1 RNA levelsInitiation of ARTHIV-1 RNA suppressionComorbid substance use disorderHealth qualityBuprenorphine/naloxoneMultidisciplinary treatment strategyOpioid-dependent patientsGeneral health qualityMental health qualityOpioid-dependent subjectsSubstance use disordersDrug Treatment Outcomes Among HIV-Infected Opioid-Dependent Patients Receiving Buprenorphine/Naloxone
Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, Bazerman LB, Chaudhry A, Cunningham CO, Gourevitch MN, Lum PJ, Sullivan LE, Schottenfeld RS, O'Connor PG. Drug Treatment Outcomes Among HIV-Infected Opioid-Dependent Patients Receiving Buprenorphine/Naloxone. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s33-s38. PMID: 21317592, PMCID: PMC3863630, DOI: 10.1097/qai.0b013e3182097537.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneBuprenorphine/naloxone treatmentOpioid-dependent patientsDrug useOpioid useNaloxone treatmentHIV treatment settingsIllicit opioid useOngoing drug useDrug treatment outcomesNaloxone dosesIllicit opioidsOpioid dependenceOffice visitsProspective studyHIV treatmentRetained patientsTreatment outcomesTreatment retentionPatientsTreatment settingsAddiction treatment processNaloxoneTreatment populationHIVImproving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine
Korthuis PT, Fiellin DA, Fu R, Lum PJ, Altice FL, Sohler N, Tozzi MJ, Asch SM, Botsko M, Fishl M, Flanigan TP, Boverman J, McCarty D. Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s83-s90. PMID: 21317600, PMCID: PMC3066190, DOI: 10.1097/qai.0b013e31820bc9a5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBuprenorphineBuprenorphine, Naloxone Drug CombinationCohort StudiesFemaleGuideline AdherenceHIV InfectionsHumansMaleMiddle AgedMultivariate AnalysisNaloxoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPractice Guidelines as TopicQuality of Health CareConceptsBUP/NXHIV careOpioid dependenceHIV qualitySummary quality scoresCare indicatorsBuprenorphine/naloxone maintenance therapyHigh-quality HIV careOpioid-dependent HIVRole of buprenorphineObservational cohort studyOpioid-dependent patientsQuality scoresNondependent patientsHIV clinicMaintenance therapyCohort studyBuprenorphine treatmentClinical outcomesMultivariable analysisMedical recordsPatientsCareMonthsHIVImproved Quality of Life for Opioid-Dependent Patients Receiving Buprenorphine Treatment in HIV Clinics
Korthuis PT, Tozzi MJ, Nandi V, Fiellin DA, Weiss L, Egan JE, Botsko M, Acosta A, Gourevitch MN, Hersh D, Hsu J, Boverman J, Altice FL. Improved Quality of Life for Opioid-Dependent Patients Receiving Buprenorphine Treatment in HIV Clinics. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s39-s45. PMID: 21317593, PMCID: PMC3073082, DOI: 10.1097/qai.0b013e318209754c.Peer-Reviewed Original ResearchConceptsSF-12 scoresGeneral US populationOpioid dependenceUS populationPoor health-related qualityShort Form Health SurveyBUP/NXBuprenorphine/naloxoneHIV care settingsOpioid-dependent patientsOpioid-dependent personsForm Health SurveyHealth-related qualityQuality of lifeBup/Mean HRQoLHIV clinicMaintenance therapyBuprenorphine treatmentHIV infectionPhysical HRQoLMental HRQOLHRQoL domainsMixed effects regressionHealth Survey